Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10530MR)

This product GTTS-WQ10530MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10530MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10023MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ1610MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ14440MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ8413MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ2599MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ3377MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ1171MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ7044MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW